ARBUTUS BIOPHARMA CORPORATION

(ABUS)
  Report
Real-time Estimate Cboe BZX  -  10:13 2022-06-27 am EDT
2.695 USD   -5.11%
09:03aARBUTUS BIOPHARMA CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/25Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
AQ
06/25Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ARBUTUS BIOPHARMA CORP : Other Events, Financial Statements and Exhibits (form 8-K)

05/24/2022 | 07:33am EDT

Item 8.01. Other Events.

On May 24, 2022, Arbutus Biopharma Corporation (the "Company") posted an updated corporate presentation on its website at www.arbutusbio.com. A copy of the Corporate Presentation is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.



Exhibit Number                           Description

  99.1             Corporate Presentation dated May 24, 2022
104              Cover page interactive data file (formatted as inline XBRL).

© Edgar Online, source Glimpses

All news about ARBUTUS BIOPHARMA CORPORATION
09:03aARBUTUS BIOPHARMA CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/25Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver ..
AQ
06/25Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver ..
GL
06/25Arbutus Biopharma Corporation Presents New Data on AB-729, Ab-836 and AB-101 At the EAS..
CI
06/09Arbutus to Present Seven Scientific Posters at EASL International Liver Congress 2022
AQ
06/08CONFERENCE CALL & WEBCAST TO DISCUSS : 00 am ET - Form 8-K
PU
06/08ARBUTUS BIOPHARMA CORP : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/08Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™..
GL
06/06Arbutus Biopharma, Vaccitech Dose First Patient in Trial Combining Therapies to Treat C..
MT
06/06ARBUTUS BIOPHARMA : Corporate Presentation - June 2022
PU
More news
Analyst Recommendations on ARBUTUS BIOPHARMA CORPORATION
More recommendations
Financials
Sales 2022 41,2 M 31,9 M 31,9 M
Net income 2022 -101 M -78,0 M -78,0 M
Net Debt 2022 - - -
P/E ratio 2022 -5,49x
Yield 2022 -
Capitalization 546 M 422 M 422 M
Capi. / Sales 2022 13,2x
Capi. / Sales 2023 17,5x
Nbr of Employees 86
Free-Float 72,9%
Chart ARBUTUS BIOPHARMA CORPORATION
Duration : Period :
Arbutus Biopharma Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARBUTUS BIOPHARMA CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,67 CAD
Average target price 8,53 CAD
Spread / Average Target 133%
EPS Revisions
Managers and Directors
William H. Collier President, Chief Executive Officer & Director
David C. Hastings Chief Financial & Accounting Officer
Frank M. Torti Chairman
Michael J. Sofia Chief Scientific Officer
Elizabeth Howard Secretary, Chief Compliance Officer & EVP
Sector and Competitors